%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is SYBLEU INC.?
intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications.
SYBE · Verdict
Moderate reward · high risk
SYBE has limited near-term tailwinds — volatility and balance sheet weigh on the model output.
Based on 88% data coverage
SYBE · Verdict
What’s working & what to watch
Watchouts 5
- Volatility5/100
Weak vs peers
- Balance sheet6/100
Current ratio 0.31
- Cash flow29/100
-860% free-cash-flow margin
- Profitability35/100
-1542% net margin · 0% ROE
- Growth41/100
Earnings +57.3% CAGR
Model-based scoring. For information only — not financial advice.
What is SYBLEU INC.?
intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 583.74K.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (44)The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.